Jiangxi Yaodu Renhe Pharmaceutical Co. Ltd.

Primary objective: To study the pharmacokinetics of a single oral dose of the test preparation oseltamivir phosphate dry suspension (specification: 6 mg/ml, licensed production by Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd.) and the reference preparation oseltamivir phosphate dry suspension (TAMIFLU®, specification: 6 mg/ml, licensed by Roche Registration GmbH, produced by Roche Pharma AG) in healthy adult subjects in the fed state, and to evaluate the bioequivalence of the two preparations in the fed state. Secondary objective: To study the safety of a single oral dose of the test preparation oseltamivir phosphate dry suspension and the reference preparation oseltamivir phosphate dry suspension (TAMIFLU®) in healthy adult subjects in the fed state.

Primary objective: To study the pharmacokinetics of a single oral dose of the test preparation oseltamivir phosphate dry suspension (specification: 6 mg/ml, licensed production by Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd.) and the reference preparation oseltamivir phosphate dry suspension (TAMIFLU®, specification: 6 mg/ml, licensed by Roche Registration GmbH, produced by Roche Pharma AG) in healthy adult subjects under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations in fasting and fed conditions. Secondary objective: To study the safety of a single oral dose of the test preparation oseltamivir phosphate dry suspension and the reference preparation oseltamivir phosphate dry suspension (TAMIFLU®) in healthy adult subjects under fasting and fed conditions.

Main purpose: Using oseltamivir phosphate capsules provided by Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd. as the test preparation, according to the relevant provisions of the bioequivalence test, the absorption rate and degree of oseltamivir phosphate capsules (trade name: Tamiflu, reference preparation) produced by Delpharm Milano S.r.l., owned by Roche Pharma (Schweiz) AG, were compared in healthy humans, and the human bioequivalence of the two preparations was investigated. Secondary purpose: To observe the safety of the test preparation oseltamivir phosphate capsules and the reference preparation (Tamiflu) in healthy subjects.